Xiaochuan Yang

Xiaochuan Yang, PhD is with the Center for Drug Evaluation and Research, FDA

Articles by Xiaochuan Yang

Regulatory Considerations for Controlled Correspondence Related to Generic Drug Chemistry

ByGeoffrey Wu,Lane Christensen,Thomas O’Connor,Frank Holcombe Jr.,Susan Rosencrance,Andre Raw,Kristina Adams,Xiaochuan Yang,Min Li

September 1st 2015

An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.

Latest Updated Articles

Regulatory Considerations for Controlled Correspondence Related to Generic Drug Chemistry
Published: September 1st 2015 | Updated:

Xiaochuan Yang

Articles by Xiaochuan Yang

Regulatory Considerations for Controlled Correspondence Related to Generic Drug Chemistry

Latest Updated Articles

Trending on Pharmaceutical Technology

Building Resilience in Pharma: Our Top 10 Questions from CPHI Frankfurt

Everything to Know About Pharmaceutical Tariffs in 2025

Challenges for the Global Manufacturing of Vaccines

Integrating Sustainability into the Core of Pharmaceutical Science

Outsourcing Partners Providing End-to-End Service